PHARMACEUTICAL IP

  • Offering
    • Evolve AI
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Biotech
    • CROs and CMOs
    • Established pharma
    • International IP counsel
    • Investors
    • Start-ups
    • Universities
  • Evolve AI
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Biotech
    • CROs and CMOs
    • Established pharma
    • International IP counsel
    • Investors
    • Start-ups
    • Universities
  • Evolve AI
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Evolve AI
  • Insights
  • Fractional IP counsel
  • Join us
  • Offering
  • Our team
  • Technologies
  • Evolve AI
  • Insights
  • Fractional IP counsel
  • Join us
  • Offering
  • Our team
  • Technologies

Universities

Universities and research institutes are where many of the most important advances in pharma and biotech begin. At Evolve, we help technology transfer offices, academic founders and research institutes protect that science in a way that makes it licensable, investable and ready for development.

For technology transfer offices with stretched teams, our fractional IP counsel model provides a named senior patent attorney who works as part of your team, triaging invention disclosures, managing portfolios and supporting licensing. Our own AI tools, developed by our attorneys specifically for pharma and biotech IP, help us assess the patentability and competitive landscape of new inventions quickly, while our attorneys make the judgement calls.

Fractional IP counsel
Evolve AI

Protecting academic inventions

Academic research moves at the pace of publication. We work with you to identify inventions early and file before papers, posters, theses and conference presentations, so that disclosure does not destroy novelty. This matters most in Europe and other markets with no general grace period for your own disclosures, even though the US and Japan give some protection for an inventor’s own earlier disclosures. We also help you decide which inventions are worth patenting, and where and when to file, so that limited patent budgets are spent where they will add the most value.

Building IP that industry wants to license

Pharmaceutical companies and investors look for IP that covers a commercially viable product, is supported by data and gives a long period of protection. Our attorneys combine scientific expertise with in-house pharma experience, so we know how licensees assess academic IP. We can shape claims and filing strategies around the likely development path, and help you present your IP clearly in licensing discussions.

Spin-outs

For spin-outs, we help define what IP is licensed or assigned to the new company, review licence terms and set up an IP strategy that will stand up to investor due diligence. We can then continue to support the company as it grows (see Start-ups).

Inventorship, ownership and collaborations

Academic research often involves several institutions, funders and industry partners. We help you establish inventorship and ownership correctly, and review collaboration, material transfer and sponsored research agreements so that IP terms are clear from the start.

Fractional IP counsel

Why fractional IP counsel for universities? Technology transfer offices have to triage many invention disclosures on limited budgets. A fractional patent director from Evolve brings the real-world industry experience that you only get working in-house and knows what licensees will look for in your IP. With our team and AI tools behind them, including Franklin for publication review, they can move quickly where a lone consultant could not, with a commercial focus that a traditional IP firm rarely brings, and a global strategic approach.

Fractional IP counsel

Read more

Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image

Franklin: AI-powered publication review for pharma

  • 23rd October 2026
Publication screening is a time sink for pharma patent attorneys. Franklin quickly finds the undisclosed inventions in a new publication submission.
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image

When do you file for a drug combination invention? (T592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

  • 24th February 2026
At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic invention.
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Sufficiency at the priority date: A study protocol is not “the same” as a therapeutic effect invention (T0883/23)

  • 31st October 2025
Therapeutic inventions are generally not considered sufficiently disclosed absent supporting data. The recent decision in T 0883/23 found that this applies both at the priority date and the filing date of the patent.
Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image
Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image

How to read a biotech patent

  • 23rd June 2025
Learn how to quickly search for and extract key information from biotech patent documents.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

The plausibility of diagnostic inventions: No data, no patent (T 0589/22)

  • 30th April 2025
Navigating the intricacies of patenting diagnostic and medical inventions can be challenging, but a recent EPO Board of Appeal decision offers crucial guidance: clear patient population definitions and robust supporting data in the initial application are paramount for establishing “plausibility” and ensuring patent validity.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

When does pre-clinical data plausibly support a therapeutic effect? (T 966/18)

  • 23rd August 2021
The timing of a patent filing is critical to the patent’s validity. The earlier a patent is filed, the lower the risk of disclosures before the priority date destroying novelty and inventive step. Yet, the later a patent application is filed, the more time there is to obtain data and satisfy the requirement that the…
View more Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Subscribe
  • Contact us